In conclusion, as a proliferation index, the expression levels of Ki-67 are correlated with KRAS- or EGFR mutations and the efficacy of first-line chemotherapy or EGFR-TKIs therapy in advanced or postoperative-recurrent NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.